focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Posting of Circular and Notice of General Meeting

23 Dec 2022 07:00

RNS Number : 6929K
Yourgene Health PLC
23 December 2022
 

 

Yourgene Health plc 

("Yourgene" or the "Company")

 

 Posting of Circular and Notice of General Meeting

 

The Board of Yourgene Health plc (AIM: YGEN), is pleased to confirm that, further to the announcements made on 21 December 2022 and 22 December 2022, regarding the proposed Capital Raising, a circular (the "Circular"), including the Notice of General Meeting and a Form of Proxy was posted yesterday to shareholders.

 

The General Meeting will be held at Skelton House, Lloyd Street North, Manchester Science Park, Manchester M15 6SH on 9 January 2023 at 4.00 p.m.

 

A copy of the Circular will shortly be available to download from the Company's website at http://www.yourgene-health.com/investors/key-documents/shareholder-communications.

 

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Circular.

 

The expected timetable relating to the Capital Raising is set out below.

 

2022

Announcement of the Capital Raising

 

21 December

Announcement of Retail Offer

 

22 December

Publication and posting of the Circular and Form of Proxy

 

22 December

First Admission and commencement of dealings in the First Admission Shares

 

8.00 a.m. on 23 December

CREST stock accounts expected to be credited for the First Admission Shares (where applicable)

 

23 December

Launch of Retail Offer

 

23 December

2023

Posting of share certificates for the First Admission Shares by the Registrar (where applicable)

 

by no later than 5 January

Latest time and date for receipt of Forms of Proxy and CREST voting instructions

 

5.00 p.m. on 5 January

Close of Retail Offer

 

6 January

General Meeting

 

4.00 p.m. on 9 January

Results of the General Meeting announced through a Regulatory Information Service

 

 9 January

Second Admission and commencement of dealings in the Second Admission Shares and the Retail Shares

 

8.00 a.m. on 11 January

Where applicable, expected date for CREST accounts to be credited in respect of Second Admission Shares in uncertificated form

 

11 January

Posting of share certificates for the Second Admission Shares by the Registrar (where applicable)

 

by no later than 24 January

Long Stop Date

 

 30 January

 

Each of the times and dates above refer to London time and are subject to change. Any such change will be notified to Shareholders by an announcement through a Regulatory Information Service. All events listed in the above timetable following the General Meeting are conditional on the passing of the Resolutions at the General Meeting.

 

Enquiries:

 

Yourgene Health plc

Lyn Rees, Chief Executive Officer

Tel: +44 (0)161 669 8122

investors@yourgene-health.com

Barry Hextall, Chief Financial Officer

Joanne Cross, Director of Marketing

 

Cairn Financial Advisers LLP (NOMAD)

Tel: +44 (0)20 7213 0880

Liam Murray / James Caithie / Ludovico Lazzaretti

 

Singer Capital Markets (Corporate Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Tom Salvesen / George Tzimas

 

Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780 or Yourgene@walbrookpr.com

Paul McManus / Lianne Applegarth

/ Alice Woodings

Mob: 07980 541 893 / 07584 391 303

/ 07407 804 654

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPGQCPUPPPUP
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.